24 September 2018 - BEAM AllianceAntibiorésistance : BEAM Alliance tire la sonnette d’alarmePriorités : Alerter les pouvoirs publics sur le besoin médical et l’urgence associés à la pénurie de nouveaux traitements contre…read more >>
07 June 2018 - BEAM AllianceBEAM writes to Representatives of the US congress to support The Pandemic and All Hazards Preparedeness Act (PAHPA) currently discussed at the House of Representatives.BEAM writes to Representatives of the US congress to support The Pandemic and All Hazards Preparedeness Act (PAHPA) currently discussed…read more >>
05 April 2018 - BEAM AllianceEU-JAMRAI: BEAM Alliance becomes a new stakeholderEU-JAMRAI [EU Joint Action on Antimicrobial Resistance (AMR) & Healthcare-Associated Infections (HCAI)] invited BEAM Alliance to take part as a new…read more >>
07 March 2018 - BEAM AllianceBEAM Alliance speaking at the 10th Community of Users Meeting – Health session “Preparedness and response to Infectious Disease Threats” in BrusselsFlorence Séjourné, President of the BEAM Alliance, presents the SME position in a round table on medical countermeasures towards policy…read more >>
15 February 2018 - BEAM AlliancePharmaceutiques, Janvier 2018 : Dossier Antibiothérapie – Incitations à l’investissementDes médicaments coûteux à développer, un marché restreint et peu prédictible : des schémas de soutien à la R&D et…read more >>
15 February 2018 - BEAM AlliancePharmaceutiques, Janvier 2018 : Dossier Antibiothérapie – Menace bactérienneFace à la montée en puissance des infections bactériennes résistantes aux antibiotiques, la communauté mondiale se met en marche. La…read more >>
20 March 2019 - Motif Bio plcMotif Bio Granted Meeting with U.S. FDA regarding Iclaprim“We are pleased that the FDA has granted our meeting request and that critical personnel from the FDA have been…read more >>
19 March 2019 - Pulmocide LtdFungal Update Meeting 2019: First Case Report of PC945 Treatment of Refectory Aspergillus Anastomotic Infection in a Lung Transplant RecipientFirst Case Report of PC945 Treatment of Refectory Aspergillus Anastomotic Infection in a Lung Transplant Recipientread more >>
18 February 2019 - NovaBiotics LtdNovaBiotics Awarded £1.8m in Small Business Research Innovation-Innovate UK grant funding to Advance its Antifungal Drug Candidate, NovamycinThe £1.8 million project aims to transform Novamycin from an exciting, laboratory-stage antifungal compound to a fully formulated antifungal drug…read more >>
14 February 2019 - Motif Bio plcMotif Bio Receives Complete Response Letter from the FDAGraham Lumsden, Chief Executive Officer of Motif Bio, said: “We are disappointed for patients and providers seeking an alternative antibiotic…read more >>
04 February 2019 - Polyphor LtdPolyphor awarded grant from CARB-X of up to $5.6M to support development of novel antibiotic against multi-drug resistant Gram-negative pathogensCARB-X provides Polyphor with initial funding of up to $2.6 million and up to $3.0 million more if certain project…read more >>
31 January 2019 - DEINOVEDeinove is preparing initiation of Phase II for DNV3837 in Clostridium difficile infections, with a key partnerDNV3837 is a first-in-class antibiotic candidate targeting the treatment of Clostridium difficile infections (CDIs), a disease classified as a priority…read more >>
14 March 201912th Berlin Conference on Life Sciences ‘Novel Antimicrobials & AMR Diagnostics 2019’Around 350 international AMR experts from SMEs, start-ups, big pharma, academia, investors and governmental institutions will meet on 14–15 March…read more >>
21 February 2019GARDP webinar: NIAID Resources to Facilitate Discovery & Development of Anti-Infectivesoverview of the various mechanisms of support offered by NIAID to facilitate the discovery and development of drugs, vaccines and…read more >>
06 February 2019Westminster Health ForumNext steps for combating antimicrobial resistance - funding, prevention and research prioritiesread more >>
29 January 2019Phage Futures CongressTranslating phage-based applications into clinically and commercially viable therapeuticsread more >>
